You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 110 No. 9, September 1992 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  CLINICAL SCIENCES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (43)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Ofloxacin vs Tobramycin for the Treatment of External Ocular Infection

Arlene Gwon, MD; for the Ofloxacin Study Group II

Arch Ophthalmol. 1992;110(9):1234-1237.


Abstract



• A multicenter, double-masked, randomized clinical investigation was conducted comparing 0.3% ofloxacin and 0.3% tobramycin for topical treatment of external ocular infection. One drop ( 1.35 µg) of either test solution was instilled six times daily for 2 days and thereafter four times daily for the next 8 days. At the day 3 to 5 follow-up examination, the severity of signs and symptoms based on a clinical summary score of 10 key variables was reduced from baseline values significantly (P<0.5) more with ofloxacin (–6.4±4.37; mean±SD) than with tobramycin (–4.78±3.13); by day 11, the difference between the groups was no longer significant. At days 3 to 5 and day 11 examinations, clinical, microbiologic, and overall improvement rates were similar, with no significant differences seen between the groups. Ofloxacin was found as effective, safe, and comfortable as tobramycin in patients with external ocular infection and may provide earlier symptom relief.



Author Affiliations



From Allergan Pharmaceuticals, Irvine, Calif.


Footnotes



Accepted for publication February 20, 1992.

Presented as a scientific exhibit at the annual meeting of the American Academy of Ophthalmology, October 28 to November 2,1989, New Orleans, La.

Reprint requests to Allergan Pharmaceuticals, 2525 Dupont Dr, Irvine, CA 92713-9534 (Dr Gwon).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials
Vidal et al.
J Antimicrob Chemother 2007;60:247-257.
ABSTRACT | FULL TEXT  

3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children
Cochereau et al.
Br J Ophthalmol 2007;91:465-469.
ABSTRACT | FULL TEXT  

Fluoroquinolones for the eye
DTB 1994;32:78-79.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.